Author(s):
Christiansen, Sara Nysom ; Rasmussen, Simon Horskjær ; Ostergaard, Mikkel ; Pons, Marion ; Michelsen, Brigitte ; Pavelka, Karel ; Codreanu, Catalin ; Ciurea, Adrian ; Glintborg, Bente ; Santos, Maria Jose ; Sari, Ismail ; Rotar, Ziga ; Gudbjornsson, Bjorn ; Macfarlane, Gary J. ; Relas, Heikki ; Iannone, Florenzo ; Laas, Karin ; Wallman, Johan K. ; van de Sande, Marleen ; Provan, Sella Aarrestad ; Castrejon, Isabel ; Zavada, Jakub ; Mogosan, Corina ; Nissen, Michael J. ; Loft, Anne Gitte ; Barcelos, Anabela ; Erez, Yesim ; Pirkmajer, Katja Perdan ; Grondal, Gerdur ; Jones, Gareth T. ; Hokkanen, Anna Mari ; Chimenti, Maria Sole ; Vorobjov, Sigrid ; Giuseppe, Daniela Di ; Kvien, Tore K. ; Otero-Varela, Lucia ; van der Horst-Bruinsma, Irene ; Hetland, Merete Lund ; Ørnbjerg, Lykke Midtbøll
Date: 2024
Persistent ID: http://hdl.handle.net/10362/172711
Origin: Repositório Institucional da UNL
Subject(s): Ankylosing; Epidemiology; Pain; Patient Reported Outcome Measures; Spondylitis; Therapeutics; Rheumatology; Immunology and Allergy; Immunology
Description
Funding Information: Novartis Pharma AG for supporting the EuroSpA collaboration. The paper has been presented at the Scandinavia Congress of Rheumatology 2023 as an oral presentation and at the EULAR 2023 Congress as a poster presentation (POS0656) with the following abstract: SNC, SHR, LMO, etc. Does radiographic status impact secukinumab effectiveness in European axial spondyloarthritis patients treated in routine care? Annals of the Rheumatic Diseases 2023;82:606-607. This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: © Author(s) (or their employer(s)) 2024.
Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
